Bifogade filer
The Board of Directors of Flerie has resolved to convert ordinary shares into series C shares under Flerie’s share redemption scheme
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
At the Extraordinary General Meeting of Flerie AB (publ) (“Flerie” or the “Company”) on 10 June 2024, it was resolved to implement a share redemption scheme. Redemption under the scheme is regulated in the Articles of Association and is carried out in two steps, conversion of ordinary shares to shares of series C followed by redemption of the shares of series C.
During the conversion period from 24 March 2026 up to and including 31 March 2026, 9,571,328 ordinary shares were submitted for conversion, representing approximately eleven (11) percent of Flerie’s total share capital. According to the Articles of Association, the maximum number of ordinary shares eligible for conversion is capped at a level requiring that the total outstanding shares of series C, following the completion of the conversion, constitute no more than five (5) percent of the Company’s total share capital. If shareholders submit ordinary shares for conversion in excess of this threshold, the number of shares to be converted shall be allocated proportionally to each shareholder’s total request for conversion.
Flerie hereby announces that the Board of Directors, in accordance with the conversion provision in the Articles of Association, has resolved to convert 4,380,078 ordinary shares into an equivalent number of shares of series C, corresponding to five (5) percent of the Company’s total share capital. Shareholders who submitted ordinary shares during the conversion period have consequently had approximately 45 percent of their requested shares converted, based on the number of ordinary shares each shareholder submitted for conversion. To the extent that the distribution did not go out evenly, distribution took place by drawing of lots.
The conversion is deemed completed once it has been registered with the Swedish Companies Registration Office and recorded in the share register.
After the conversion has been completed, the total number of shares and votes in Flerie will remain 87,601,573. The total number of shares will consist of 83,221,495 ordinary shares and 4,380,078 shares of series C.
Shares of series C carry one vote per share and do not entitle their holders to receive dividends.
As soon as practicable after the publication of the Company’s interim report for the first quarter of 2026, the Board of Directors intends to resolve on the redemption of all outstanding shares of series C. The redemption amount for each share of series C will correspond to its net asset value as of 31 March 2026, as reported in the interim report for the first quarter of 2026.
For more information, please contact:
Ted Fjällman, CEO of Flerie
E-mail: ir@flerie.com
Telephone: +46 (0)76 600 89 26
The information was submitted for publication, through the agency of the contact person above, on 31 March 2026, at 19:05 CEST.
About Flerie
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com.